Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Other

Sansho Seiyaku Kabushiki Kaisha

Hayashibara Co., Ltd.

Seibutsu Kagaku Kenkyujo

Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

Masashi Kurimoto

Kakuji Torigoe

Keizo Kohno

Tadao Tanimoto

Toshio Kunikata

Mutsuko Taniguchi

Masakazu Mitsuhashi

Haruki Okamura

Madoka Taniai

Kozo Yamamoto

Takeshi Ario

Shimpei Ushio

Shigeharu Fukuda

Tsunetaka Ohta

Takanori Okura

Kanso Iwaki

Osamu Sano

Shigeyuki Arai

Mitsukiyo Fujii

Yoshiyuki Nukada

Kenji Akita

Iwao Okamoto

Yoshiaki Yanai

Toshihiko Matsuo

Hiroshi Yamauchi

Tetsuo Kimoto

Yasushi Nishizaki

Yasuaki Oyama

Toshi Kunikata

Todao Tanimoto

Hiroto Chaen

Kaname Sugimoto

Hajime Aga

Shinsaku Nakagawa

Tadanori Mayumi

Yasuo Tsutsumi

Katsuhiko Hino

Masaki Miyake

Ryuichi Motoda

Yutaka Mishima

Mamoru Hirao

Harumi Ariyasu

Nicole Joy Horwood

Nobuyuki Udagawa

Chiyo Yoshizane

Kunihiro Ohashi

Yuyaka Mishima

Yasuo Suemoto

Manami Sawatani

Hiroyoshi Tahata

Noboru Izumi

Akira Harashima

Kazue Takayama

Osamu Sanou

Norie Arai

Eikichi Miyake

Matthew Todd Gillispie

The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.

Agent for strengthening calcium containing tissue and use thereof

A protein which induces the IFN-&#x3b3; production by immunocompetent cells and has a molecular weight of 19,000&#xb1;5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8&#xb1;1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein.

IFN-&#x3b3; production inducing protein (IGIF, IL-18)

An ophthalmic pharmaceutical composition comprising trehalose as an effective ingredient and a pharmaceutically-acceptable carrier. The pharmaceutical composition is a safe, long-term continuously-administrable, therapeutic and/or prophylactic agent for the ophthalmologic clinical symptoms and signs in Sj&#xf6;gren syndrome.

Pharmaceutical composition for ophthalmic use

The present invention has objects to provide a mutant interferon-&#x3b1; protein having a higher anti-viral and anti-tumor activity and to provide an agent for susceptive diseases, which contains the mutant interferon-&#x3b1; protein as an effective ingredient; and solves the above objects by providing a mutant protein which has an amino acid sequence of human interferon-&#x3b1; subtype &#x3b1;8 represented by any one of SEQ ID NOs:1 to 3, where the arginine residue at the 145has been replaced with leucine, isoleucine, or valine residue; the alanine residue at the 146has been replaced with asparagine or serine residue; and the methionine residue at the 149has been replaced with tyrosine residue; and an agent for susceptive diseases, containing the mutant protein.

Mutant interferon &#x3b1; protein and use thereof

A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18,500&#xb1;3,000 daltons on SDS-PAGE and a pI of 4.9&#xb1;1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-&#x3b3; production by immunocompetent cells with only a small amount, and dose not cause serious side effects even when administered to human in a relatively-high dose.

Method for detecting a polypeptide which induces interferon-&#x3b3;  production

A human IFN-&#x3b3; inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel INF-&#x3b3; inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with INF-&#x3b3;, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Interferon-&#x3b3; inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use

It is intended to provide an anti-allergic agent, which efficaciously relieves symptoms accompanying an allergic disease without causing any serious side effect. This object is achieved by providing an anti-allergic agent which contains, as an effective ingredient, proteins collected from royal jelly or purified royal jelly, or royal jelly or purified royal jelly containing the proteins.

Antiallergic agent

The objects of the present invention are to reveal a specific combination of human interferon-&#x3b1; subtypes that remarkably enhances the expression of protein synthesis inhibitory genes, and to provide an expression enhancer comprising as effective ingredients interferon-&#x3b1; subtypes in such a combination and uses thereof. The above objects are solved by providing an expression enhancer for protein synthesis inhibitory genes which comprises as effective ingredients interferon-&#x3b1;2 and interferon-&#x3b1;8 subtypes of human interferon-&#x3b1;, and uses thereof including pharmaceuticals.

Pharmaceutical composition of human interferon-&#x3b1;2 and interferon &#x3b1;8 subtypes

Disclosed are a receptor protein which recognize a novel cytokine, i.e., interleukin-18, a monoclonal antibody specific to the protein, and uses thereof. The receptor protein is useful as pharmaceutical to treat and prevent autoimmune and allergic disease because it suppresses and regulates excessive immunoreaction. The monoclonal antibody specifically reacts with interleukin-18, exhibiting efficacy in purification, detection and inhibition of interleukin-18.

Interleukin-18-receptor proteins

A human IFN-&#x3b3; inducing polypeptide and its nucleotide sequence was isolated, purified and characterized. Pharmaceutical compositions containing this novel IFN-&#x3b3; inducing polypeptide or active fragments thereof are formulated and monoclonal antibodies are raised against this polypeptide or antigenic fragments thereof. The polypeptide can be used in a method for treating diseases susceptive to treatment with IFN-&#x3b3;, and methods for enhancing the cytotoxicity of NK cells or for inducing the formation of LAK cells, such as to treat tumors and malignant pathologies.

Disclosed are created stable polypeptides which are capable of inducing the production of interferon-gamma by immunocompetent cells. The present polypeptides contain specific amino acid sequences usually derived from the wild-type polypeptides, being capable of the production of interferon-gamma, by replacing the cysteine(s) with different amino acid(s). The present polypeptides possess a stability and an activity of inducing the production of IFN-&#x3b3; by immunocompetent cells, both of which are significantly higher than those of the wild-type polypeptides. In addition to the activity, the present polypeptides can exhibit remarkable activities of inducing the formation of killer cells and enhancing thier cytotoxicities. The present polypeptides are easily obtainable by the process according to the present invention using recombinant DNA techniques. Thus the present polypeptides are useful for agents to treat and/or prevent susceptive diseases such as viral diseases, infections, malignant tumors, and immunopathies.

DNA encoding loypeptides having interferon-&#x3b3; inducing activity

An osteoclastgenic inhibitory agent which comprises an interleukin-18 and/or its functional equivalent. The agent can be arbitrarily used as an ingredient for cell culture and agents for regulating bone resorption and for osteoclast-related diseases, directed to treat and/or prevent hypercalcemia, osteoclastoma, osteoporosis, etc.

Method for treating a disease associated with excessive osteoclast formation

Disclosed is a genomic DNA encoding a polypeptide capable of inducing the production of interferon-&ggr; by immunocompetent cells. The genomic DNA efficiently expresses the polypeptide with high biological activities of such as inducing the production of interferon-&ggr; by immunocompetent cells, enhancing killer cells' cytotoxicity and inducing killer cells' formation, when introduced into mammalian host cells. The high biological activities of the polypeptide facilitate its uses to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases and immune diseases without serious side effects when administered to humans.

Genomic DNA encoding a polypeptide capable of inducing the production of interferon-&ggr;

The objects of the present invention are to reveal a specific combination of human interferon-&agr; subtypes that remarkably enhances the expression of protein synthesis inhibitory genes, and to provide an expression enhancer comprising as effective ingredients interferon-&agr; subtypes in such a combination and uses thereof. The above objects are solved by providing an expression enhancer for protein synthesis inhibitory genes which comprises as effective ingredients interferon-&agr;2 and interferon-&agr;8 subtypes of human interferon-&agr;, and uses thereof including pharmaceuticals.

Expression enhancer for protein synthesis inhibitory genes

Disclosed are a DNA which encodes murine trehalase, a polypeptide expressed by the DNA, and a transgenic- and knockout- animals which have been genetically engineered with the DNA. The DNA comprises a part or the whole of the nucleotide sequence of SEQ ID NO:1.

DNA which encodes trehalase and uses thereof

Growing community of inventors

Okayama, Japan

Masashi Kurimoto